Oppenheimer lowers Allogene Therapeutics shares goal citing revised market assumptions By Investing.com
On Tuesday, Oppenheimer adjusted its value goal for Allogene Therapeutics (NASDAQ:) shares…
Nektar Therapeutics CEO sells shares price over $29,000 By Investing.com
Nektar Therapeutics (NASDAQ:) President and CEO, Howard W. Robin, has just lately…
Dyne therapeutics govt sells over $78k in inventory By Investing.com
WALTHAM, MA – Dyne Therapeutics, Inc. (NASDAQ:DYN) Chief Enterprise Officer Jonathan McNeill…
Wall Avenue eyes Alnylam’s RNAi therapeutics potential By Investing.com
Up to date Monetary Article: Alnylam Prescribed drugs' Strategic Concentrate on RNAi…
